Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes

Background and aims.The reduced action of incretin hormones in type 2 diabetes (T2D) is mainly attributed to GIP insensitivity, but efficacy estimates of GIP and GLP-1 differ among studies, and the negligible effects of pharmacological GIP doses remain unexplained. We aimed to characterize incretin action in vivo in subjects with normal glucose tolerance (NGT) or T2D and provide an explanation for the different insulinotropic activity of GIP and GLP-1 in T2D subjects.

Source: Metabolism - Clinical and Experimental - October 30, 2020 Category: Biomedical Science Authors: Eleonora Grespan, Toni Giorgino, Andrea Natali, Ele Ferrannini, Andrea Mari Source Type: research